SG11201803461RA - An ex vivo method for testing cellular responsiveness of primary cell populations to a drug or combination of drugs - Google Patents

An ex vivo method for testing cellular responsiveness of primary cell populations to a drug or combination of drugs

Info

Publication number
SG11201803461RA
SG11201803461RA SG11201803461RA SG11201803461RA SG11201803461RA SG 11201803461R A SG11201803461R A SG 11201803461RA SG 11201803461R A SG11201803461R A SG 11201803461RA SG 11201803461R A SG11201803461R A SG 11201803461RA SG 11201803461R A SG11201803461R A SG 11201803461RA
Authority
SG
Singapore
Prior art keywords
drugs
drug
combination
primary cell
cell populations
Prior art date
Application number
SG11201803461RA
Inventor
Nobell Juan Antonio Ballesteros
Teresa Bennett
Ramos Daniel Primo
Ghia Paolo Prospero
Oquillas Ana Belén Espinosa
Guillén Julián Gorrochategui
Mateos Alicia Robles
Campo Pilar Hernández
Original Assignee
Vivia Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivia Biotech Sl filed Critical Vivia Biotech Sl
Publication of SG11201803461RA publication Critical patent/SG11201803461RA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides, bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201803461RA 2015-11-04 2016-11-04 An ex vivo method for testing cellular responsiveness of primary cell populations to a drug or combination of drugs SG11201803461RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250687P 2015-11-04 2015-11-04
PCT/EP2016/076690 WO2017077046A1 (en) 2015-11-04 2016-11-04 An ex vivo method for testing cellular responsiveness of primary cell populations to a drug or combination of drugs

Publications (1)

Publication Number Publication Date
SG11201803461RA true SG11201803461RA (en) 2018-05-30

Family

ID=57421814

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803461RA SG11201803461RA (en) 2015-11-04 2016-11-04 An ex vivo method for testing cellular responsiveness of primary cell populations to a drug or combination of drugs

Country Status (14)

Country Link
US (1) US20190212325A1 (en)
EP (1) EP3371595B1 (en)
JP (1) JP6774685B2 (en)
KR (1) KR20180070603A (en)
CN (1) CN108351345B (en)
AU (1) AU2016348722A1 (en)
BR (1) BR112018008928A2 (en)
CA (1) CA3003347A1 (en)
CL (1) CL2018001138A1 (en)
HK (1) HK1258451A1 (en)
IL (1) IL259013A (en)
MX (1) MX2018005228A (en)
SG (1) SG11201803461RA (en)
WO (1) WO2017077046A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111089977A (en) * 2019-12-30 2020-05-01 浙江科途医学科技有限公司 Method for detecting oncolytic virus effectiveness by using organoid
CN117192115A (en) * 2023-11-03 2023-12-08 赛德特(北京)生物工程有限公司 Method for detecting T lymphocyte immunocompetence

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114013A1 (en) * 2008-03-12 2009-09-17 Vaxdesign Corp. Disease model incorporation into an artificial immune system (ais)
TW201024733A (en) * 2008-09-26 2010-07-01 Sanofi Aventis Methods for determining sodium-proton-exchanger ligand efficiency
US20120213706A1 (en) * 2009-04-15 2012-08-23 University Of Medicine And Dentistry Of New Jersey Reconstituted tumor microenvironment for anticancer drug development
EP2433124B1 (en) * 2009-05-19 2017-03-01 Vivia Biotech S.L. Methods for providing personalized medicine tests ex vivo for hematological neoplasms
US10295530B2 (en) * 2012-08-28 2019-05-21 The Brigham And Women's Hospital, Inc. Functional assay for cancer recurrence and malignant potential
US9958432B2 (en) * 2013-09-20 2018-05-01 Lynx Biosciences, Inc. Cellular cis-co-culture systems for analysis

Also Published As

Publication number Publication date
EP3371595A1 (en) 2018-09-12
AU2016348722A1 (en) 2018-05-17
CL2018001138A1 (en) 2018-10-12
CA3003347A1 (en) 2017-05-11
MX2018005228A (en) 2018-08-15
EP3371595B1 (en) 2019-12-25
CN108351345A (en) 2018-07-31
BR112018008928A2 (en) 2019-04-30
KR20180070603A (en) 2018-06-26
CN108351345B (en) 2021-11-30
IL259013A (en) 2018-06-28
HK1258451A1 (en) 2019-11-15
US20190212325A1 (en) 2019-07-11
JP6774685B2 (en) 2020-10-28
JP2018533728A (en) 2018-11-15
WO2017077046A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
IL292504B1 (en) -methods of preparing t cells for t cell therapy
IL284172A (en) Diagnostic methods for t cell therapy
FI3198035T3 (en) Methods for predicting drug responsiveness
CL2014003531A1 (en) Diodegradable drug supply for hydrophobic compositions and their method of preparation.
PL3255720T3 (en) Battery module comprising probe for sensing expansion of battery cell
BR112016018105A2 (en) electrochemical cell, method of producing an electrochemical cell
SG11201609091YA (en) Method for assessing state of differentiation of cells
DK3227435T3 (en) GAMMA DELTA T cell expansion PROCEDURE
DK2879615T3 (en) Method of determining probability of rupture
HK1225636A1 (en) Method for enhanced production of morinda metabolites
IL259770B (en) Method of preparing glucosylceramide synthase inhibitors
HK1250931A1 (en) Methods for inducing cell division of postmitotic cells
HK1257768A1 (en) Use of eb1 as a biomarker of drug response
HK1258451A1 (en) An ex vivo method for testing cellular responsiveness of primary cell populations to a drug or combination of drugs
GB2531169B (en) Method for determining degree of modified potency of bipathic medicament
ES2717715T3 (en) Pharmaceutical composition comprising polymorph IV of ivabradine hydrochloride
HUP1300526A2 (en) Method for thermoacoustic localization of solid segregations
IL262553B (en) Technology for efficient activation of nkt cells
GB201414419D0 (en) Method of testing
HK1248774A1 (en) Cell measurement method
HK1232209A1 (en) Method for the preparation of (s)-2-acetyloxypropionic acid and derivatives thereof (s)-2-
EP3302397C0 (en) Syringe for cell isolation
GB201523177D0 (en) Sodium loxoprofen drug intermediates 1- p-tolyl-2-chloro-1-propanone synthesis method
GB201523176D0 (en) Lobenzarit drug intermediates N- o-carboxyphenyl-4-chloro-anthranilic acid synthesis method
GB201518671D0 (en) Method for enrichment of cell free nucleosomes of disease origin